초록 ▼

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface h

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. For example, the present invention nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.

대표청구항 ▼

1. A composition comprising (1) synthetic nanocarriers comprising a polymeric or lipid surface presenting thereon an immunofeature surface formed of an array of a plurality of nicotine moieties having the structure shown below or a metabolite thereof, wherein the nicotine or metabolite is covalently

1. A composition comprising (1) synthetic nanocarriers comprising a polymeric or lipid surface presenting thereon an immunofeature surface formed of an array of a plurality of nicotine moieties having the structure shown below or a metabolite thereof, wherein the nicotine or metabolite is covalently bound to the polymer or lipid at one of R1-R7 and the remainder of R1-R7 are selected from the group consisting of H, alkyl, aryl, alkoxy, aryloxy, alkaryl, and aralkyl, any of which may be substituted or unsubstituted and may contain one or more heteroatoms;R8 is an alkyl group;wherein the array binds to antigen presenting cell surfaces with high avidity and low affinity as compared to antibody binding;the nanocarriers optionally comprising one or more targeting agents recognizing a target associated with a particular organ, tissue, cell, or subcellular locale and optionally comprising one or more immunomodulatory agents inducing an immune response in B or T cells, or stimulating the immune system in a manner that enhances, suppresses, directs, or redirects an immune response, and(2) a pharmaceutically acceptable excipient. 2. The composition of claim 1, wherein the nanocarriers comprise one or more targeting agents recognizing a target associated with a particular organ, tissue, cell, or subcellular locale or one or more immunomodulatory agents or one or more immunostimulatory agents inducing an immune response in B or T cells, or stimulating the immune system in a manner that enhances, suppresses, directs, or redirects an immune response, wherein the targeting agents or immunomodulatory agents are associated with the surface of the nanocarriers or encapsulated within the nanocarriers. 3. The composition of claim 1, wherein the synthetic nanocarriers are capable of activating antigen presenting cells, B cells, CD4+ T cells, NKT cells, or any combination of these cell types when administered to a human. 4. The composition of claim 1, wherein the synthetic nanocarriers are capable of stimulating production of anti-nicotine IgG antibodies when administered to a human. 5. The composition of claim 1, wherein the synthetic nanocarriers are capable of eliciting a humoral immune response in a human subject. 6. The composition of claim 1, wherein, when the synthetic nanocarriers are administered to a human subject, the synthetic nanocarriers are capable of being translocated across a subcapsular sinus (SCS) floor by SCS macrophages in the subject. 7. The composition of claim 2, wherein the immunostimulatory agent is selected from the group consisting of a TLR agonist, an interleukin, an interferon, a cytokine, a CD40 agonist, an inflammasome agonist and an adjuvant. 8. The composition of claim 1, wherein the synthetic nanocarriers comprises polymer molecules, and wherein the plurality of nicotine moieties are covalently attached to the polymer molecules. 9. The composition of claim 8, wherein the plurality of nicotine moieties are (S)-(−)-nicotine moieties, and wherein the synthetic nanocarriers comprise a polymer having the structure of (X)n-L1-(Y)m-L2-A, wherein X is a hydrophobic polymer segment; Y is a hydrophilic polymer segment; n and m are selected from 0 and 1, provided that n and m are not both 0; L1 and L2 are independently selected from a bond and a linking group; and A is (S)-(−)-nicotine. 10. The composition of claim 1, wherein R8 is methyl. 11. The composition of claim 1, wherein the nicotine is present on the surface of the nanocarriers in a density equal to or greater than the density required to obtain at least 10% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell (APC) binding assay, provided that, in the APC binding assay, the half maximal binding density for the plurality of moieties is at least twice the half maximal binding density for the MAb. 12. The composition of claim 11, wherein the nicotine is present on the surface of the nanocarriers in a density equal to or greater than the density required to obtain at least 20% of the maximal immobilization observed for a MAb in the APC binding assay. 13. The composition of claim 11, wherein the MAb is anti-CD1c (BDCA-1) Clone AD5-8E7, or rat anti-mouse CD169, clone 3D6.112, isotype IgG2a and the half maximal binding density for the nicotine is at least four times the half maximal binding density for the MAb. 14. The composition of claim 11, wherein the APC binding assay comprises (a) preparing a series of substrates having coatings of a functional moiety at a series of surface coating densities, wherein the functional moiety is capable of binding to dendritic cell (DC) or subcapsular sinus macrophage surface receptors;(b) exposing the series of substrates to single-cell suspensions of DCs or subcapsular sinus macrophages for a predetermined period of time;(c) removing non-adhered APCs from the series of substrates, and fixing the adhered APCs to the series of substrates;(d) quantifying the number of adhered APCs per unit surface area for each substrate in the series of substrates;(e) plotting the result from (d) against the coating density of the functional moiety;(f) obtaining a value for the maximal immobilization by determining the maximum number of adhered APCs per unit surface area for the series of substrates; and(g) obtaining a value for half maximal binding density by determining the surface coating density that provides 50% of the maximum. 15. The composition of claim 1, wherein the nicotine is covalently bound to a lipid headgroup. 16. The composition of claim 1, wherein the nicotine comprises a metabolite of nicotine. 17. A method comprising administering a composition comprising (1) synthetic nanocarriers comprising a polymeric or lipid surface presenting thereon an immunofeature surface formed of an array of nicotine moieties having the structure shown below or a metabolite thereof, wherein the nicotine or metabolite is covalently bound to the polymer or lipid at one of R1-R7 and the remainder of R1-R7 are selected from the group consisting of H, alkyl, aryl, alkoxy, aryloxy, alkaryl, and aralkyl, any of which may be substituted or unsubstituted and may contain one or more heteroatoms;R8 is an alkyl group;wherein the array binds to antigen presenting cell surfaces with high avidity and low affinity as compared to antibody binding;the nanocarriers optionally comprising one or more targeting agents recognizing a target associated with a particular organ, tissue, cell, or subcellular locale and optionally comprising one or more immunomodulatory agents inducing an immune response in B or T cells, or stimulating the immune system in a manner that enhances, suppresses, directs, or redirects an immune response, and(2) a pharmaceutically acceptable excipient,to a subject having a baseline IgG anti-nicotine antibody serum concentration of less than 100 ng/ml, wherein a post-administration anti-nicotine IgG antibody peak serum concentration in the subject is more than 200 ng/ml. 18. A method comprising administering a composition comprising (1) synthetic nanocarriers comprising a polymeric or lipid surface presenting thereon an immunofeature surface formed of an array of nicotine moieties having the structure shown below or a metabolite thereof, wherein the nicotine or metabolite is covalently bound to the polymer or lipid at one of R1-R7 and the remainder of R1-R7 are selected from the group consisting of H, alkyl, aryl, alkoxy, aryloxy, alkaryl, and aralkyl, any of which may be substituted or unsubstituted and may contain one or more heteroatoms;R8 is an alkyl group;wherein the array binds to antigen presenting cell surfaces with high avidity and low affinity as compared to antibody binding;the nanocarriers optionally comprising one or more targeting agents recognizing a target associated with a particular organ, tissue, cell, or subcellular locale and optionally comprising one or more immunomodulatory agents inducing an immune response in B or T cells, or stimulating the immune system in a manner that enhances, suppresses, directs, or redirects an immune response, and(2) a pharmaceutically acceptable excipient,to a subject that has not been previously vaccinated against nicotine, wherein a post-administration anti-nicotine antibody peak concentration in the subject is greater than or equal to 100 ng/ml. 19. A method comprising administering to a subject an initial dose of a composition comprising (1) synthetic nanocarriers comprising a polymeric or lipid surface presenting thereon an immunofeature surface formed of an array of nicotine moieties having the structure shown below or a metabolite thereof, wherein the nicotine or metabolite is covalently bound to the polymer or lipid at one of R1-R7 and the remainder of R1-R7 are selected from the group consisting of H, alkyl, aryl, alkoxy, aryloxy, alkaryl, and aralkyl, any of which may be substituted or unsubstituted and may contain one or more heteroatoms;R8 is an alkyl group;wherein the array binds to antigen presenting cell surfaces with high avidity and low affinity as compared to antibody binding;the nanocarriers optionally comprising one or more targeting agents recognizing a target associated with a particular organ, tissue, cell, or subcellular locale and optionally comprising one or more immunomodulatory agents inducing an immune response in B or T cells, or stimulating the immune system in a manner that enhances, suppresses, directs, or redirects an immune response, and(2) a pharmaceutically acceptable excipient; andadministering to the subject a first subsequent dose of the composition at a time period after the administration of the initial dose. 20. The method of claim 19, wherein the time period after the administration of the initial dose is between 1 day and 1 year. 21. The method of claim 19, further comprising administering to the subject a second subsequent dose of the composition at a time period after the administration of the first subsequent dose. 22. The method of claim 21, wherein the time period after the administration of the first subsequent dose is between 1 day and 1 year. 23. The composition of claim 1 wherein the nanocarrier is a self-assembling synthetic nanocarrier formed of amphiphilic molecules, comprising hydrophilic immunomodulatory or antigen molecules covalently bound to a hydrophobic polymer or amphiphilic lipids. 24. The composition of claim 9 wherein the hydrophilic polymer is polyethylene glycol and the hydrophobic polymer is selected from the group consisting of polyglycolic acid, polylactic acid, and poly(glycolic-lactic acid). 25. The composition of claim 1 wherein the nanocarriers comprise lipid and polymer, and the nicotine or metabolite is bound to the lipid, polymer or both.